Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on Thursday.

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...